Buserelin Acetate (Suprefact®)

Buserelin Acetate (SuCommon name: Buserelin Acetate
Brand name: Suprefact®


What is Buserelin Acetate?

Buserelin Acetate is a luteinizing hormone releasing hormone (LHRH) analogue that is used in the palliative treatment of advanced (metastatic) prostate cancer. Buserelin acetate works by blocking the production of testosterone which reduces the growth and reproduction of prostate cancer cells.
 

How is Buserelin Acetate administered?

Buserelin Acetate is by administered by subcutaneous injection or as a nasal solution.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received buserelin acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
 
  • Diarrhea
  • Dizziness
  • Dry mouth
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Nausea / vomiting
  • Reduced sexual desire (low libido)


Is Buserelin Acetate covered in my province or territory?

Buserelin acetate is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • Manitoba
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
  • Nunavut
  • Northwest Territories
  • Yukon
Buserelin acetate is not covered by provincial drug programs in:
  • Prince Edward Island
 
Last Reviewed: July 2017

 
   
   

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More

Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More


Click here for news archive